UA85471C2 - Применение оксикодона для лечения висцеральной боли - Google Patents

Применение оксикодона для лечения висцеральной боли

Info

Publication number
UA85471C2
UA85471C2 UAA200708142A UAA200708142A UA85471C2 UA 85471 C2 UA85471 C2 UA 85471C2 UA A200708142 A UAA200708142 A UA A200708142A UA A200708142 A UAA200708142 A UA A200708142A UA 85471 C2 UA85471 C2 UA 85471C2
Authority
UA
Ukraine
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
UAA200708142A
Other languages
English (en)
Ukrainian (uk)
Inventor
Асбйорн Мор Древес
Ларс Арендт Нильсен
Original Assignee
Евро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85471(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Евро-Селтик С.А. filed Critical Евро-Селтик С.А.
Publication of UA85471C2 publication Critical patent/UA85471C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к лечению висцеральной боли с применением оксикодона или его фармацевтически приемлемых солей.
UAA200708142A 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли UA85471C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
UA85471C2 true UA85471C2 (ru) 2009-01-26

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200708142A UA85471C2 (ru) 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли

Country Status (32)

Country Link
US (2) US20080200493A1 (ru)
EP (1) EP1838318B1 (ru)
JP (1) JP5049139B2 (ru)
KR (10) KR20190135557A (ru)
CN (1) CN101106996B (ru)
AP (1) AP2249A (ru)
AR (1) AR052880A1 (ru)
AT (2) ATE446092T1 (ru)
AU (1) AU2006207498B2 (ru)
BR (1) BRPI0606247A2 (ru)
CA (1) CA2595043C (ru)
CY (1) CY1109660T1 (ru)
DE (2) DE202006019887U1 (ru)
DK (2) DK1838318T3 (ru)
EA (1) EA013544B1 (ru)
ES (1) ES2333901T3 (ru)
HK (1) HK1107933A1 (ru)
HR (1) HRP20090679T1 (ru)
IL (1) IL184530A (ru)
ME (1) ME01066B (ru)
MX (1) MX2007007207A (ru)
MY (1) MY144471A (ru)
NO (1) NO338968B1 (ru)
NZ (1) NZ555852A (ru)
PL (1) PL1838318T3 (ru)
PT (1) PT1838318E (ru)
RS (1) RS51069B (ru)
SI (1) SI1838318T1 (ru)
TW (1) TWI432196B (ru)
UA (1) UA85471C2 (ru)
WO (1) WO2006077212A1 (ru)
ZA (1) ZA200705231B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57194B1 (sr) 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
EP3165236B1 (en) * 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
LT3495392T (lt) 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (ru) * 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
DK1838318T3 (da) 2010-01-04
HK1107933A1 (en) 2008-04-25
DE202006019887U1 (de) 2007-07-26
AU2006207498A1 (en) 2006-07-27
CA2595043C (en) 2013-11-19
ZA200705231B (en) 2008-06-25
TW200637554A (en) 2006-11-01
AT9895U1 (de) 2008-05-15
US20150190393A1 (en) 2015-07-09
JP5049139B2 (ja) 2012-10-17
CA2595043A1 (en) 2006-07-27
WO2006077212A1 (en) 2006-07-27
MY144471A (en) 2011-09-30
NO20074174L (no) 2007-10-17
EA013544B1 (ru) 2010-06-30
CY1109660T1 (el) 2014-08-13
KR20190135557A (ko) 2019-12-06
DK200700207U1 (da) 2007-08-24
KR20210131450A (ko) 2021-11-02
ME01066B (me) 2012-10-20
CN101106996A (zh) 2008-01-16
AP2249A (en) 2011-07-18
RS51069B (sr) 2010-10-31
PL1838318T3 (pl) 2010-03-31
AP2007004057A0 (en) 2007-08-31
EP1838318A1 (en) 2007-10-03
BRPI0606247A2 (pt) 2009-06-09
US20080200493A1 (en) 2008-08-21
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
EP1838318B1 (en) 2009-10-21
PT1838318E (pt) 2009-12-15
KR20080106991A (ko) 2008-12-09
NO338968B1 (no) 2016-11-07
US9271974B2 (en) 2016-03-01
CN101106996B (zh) 2013-10-23
ATE446092T1 (de) 2009-11-15
AU2006207498B2 (en) 2009-11-19
DK200700207U3 (da) 2007-09-28
EA200701541A1 (ru) 2008-02-28
HRP20090679T1 (hr) 2010-01-31
DE602006009899D1 (de) 2009-12-03
JP2008526927A (ja) 2008-07-24
KR20220165797A (ko) 2022-12-15
KR20200128451A (ko) 2020-11-12
KR20140091782A (ko) 2014-07-22
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
KR20070100368A (ko) 2007-10-10
TWI432196B (zh) 2014-04-01
KR20120089710A (ko) 2012-08-13
NZ555852A (en) 2010-01-29
KR20230170811A (ko) 2023-12-19
SI1838318T1 (sl) 2010-02-26
IL184530A0 (en) 2007-10-31
ES2333901T3 (es) 2010-03-02

Similar Documents

Publication Publication Date Title
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
EP1744751A4 (en) TREATMENT OF SYNUCLEINOPATHIES
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL188430A0 (en) Treatment of tumors
IL201422A0 (en) Therapeutic agents useful for treating pain
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
TW200733976A (en) Method for the treatment of cognitive dysfunction
IL178827A0 (en) Use of reboxetine for the treatment of pain
EP1894588A4 (en) NEEDLE FOR MEDICAL TREATMENT
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
EP1732549A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EP1871462A4 (en) DC TISSUE TREATMENT
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
ZA200904478B (en) Novel therapeutic use for treating leukaemia
GB0415181D0 (en) Compounds for use in the treatment of infection
GB0503382D0 (en) Tissue treatment system
ZA200606780B (en) Compounds for the treatment of diseases
ATE468852T1 (de) Lofexidine zur intraspinalen anwendung
GB0412262D0 (en) Use of compounds for the treatment of pain